https://www.biospace.com/substance-use-disorders Substance use disorders en-US Tue, 25 Aug 2026 12:06:10 GMT https://www.biospace.com/press-releases/astrocyte-pharmaceuticals-receives-nih-award-to-evaluate-ast-004-in-substance-use-disorders Tue, 25 Aug 2026 12:06:10 GMT https://www.biospace.com/press-releases/astrocyte-pharmaceuticals-receives-nih-award-to-evaluate-ast-004-in-substance-use-disorders https://www.biospace.com/press-releases/amygdala-neurosciences-announces-fda-clearance-of-investigational-new-drug-ind-application-for-ans-858 Tue, 18 Aug 2026 10:30:56 GMT https://www.biospace.com/press-releases/amygdala-neurosciences-announces-fda-clearance-of-investigational-new-drug-ind-application-for-ans-858 https://www.biospace.com/press-releases/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder Tue, 28 Jul 2026 13:00:05 GMT https://www.biospace.com/press-releases/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder https://www.biospace.com/press-releases/tris-pharma-to-present-on-dual-nop-mop-receptor-agonist-in-pain-management-and-substance-use-disorder-at-the-college-on-problems-of-drug-dependence-cpdd-88th-annual-scientific-meeting-2026 Thu, 11 Jun 2026 13:15:53 GMT https://www.biospace.com/press-releases/tris-pharma-to-present-on-dual-nop-mop-receptor-agonist-in-pain-management-and-substance-use-disorder-at-the-college-on-problems-of-drug-dependence-cpdd-88th-annual-scientific-meeting-2026 https://www.biospace.com/press-releases/newleos-announces-dosing-of-first-participant-in-phase-1b-study-of-ntx-2001-for-alcohol-use-disorder Wed, 29 Apr 2026 15:06:06 GMT https://www.biospace.com/press-releases/newleos-announces-dosing-of-first-participant-in-phase-1b-study-of-ntx-2001-for-alcohol-use-disorder https://www.biospace.com/press-releases/demerx-announces-fda-acceptance-of-ind-application-to-advance-dmx-1001-for-the-treatment-of-alcohol-use-disorder-aud Thu, 23 Apr 2026 07:05:59 GMT https://www.biospace.com/press-releases/demerx-announces-fda-acceptance-of-ind-application-to-advance-dmx-1001-for-the-treatment-of-alcohol-use-disorder-aud https://www.biospace.com/press-releases/adial-pharmaceuticals-commends-congress-on-introduction-of-bipartisan-legislation-expanding-access-to-emerging-aud-therapies-for-veterans Wed, 25 Mar 2026 01:05:41 GMT https://www.biospace.com/press-releases/adial-pharmaceuticals-commends-congress-on-introduction-of-bipartisan-legislation-expanding-access-to-emerging-aud-therapies-for-veterans https://www.biospace.com/press-releases/clearmind-medicine-reports-successful-ongoing-treatment-of-participants-at-us-sites-in-its-fda-approved-cmnd-100-phase-i-iia-clinical-trial-for-alcohol-use-disorder Thu, 19 Mar 2026 13:21:06 GMT https://www.biospace.com/press-releases/clearmind-medicine-reports-successful-ongoing-treatment-of-participants-at-us-sites-in-its-fda-approved-cmnd-100-phase-i-iia-clinical-trial-for-alcohol-use-disorder https://www.biospace.com/press-releases/baseline-therapeutics-launches-to-advance-glp-1ra-phase-3-program-in-alcohol-use-disorder Wed, 28 Jan 2026 14:08:24 GMT https://www.biospace.com/press-releases/baseline-therapeutics-launches-to-advance-glp-1ra-phase-3-program-in-alcohol-use-disorder https://www.biospace.com/press-releases/lunai-bioworks-nasdaq-lnai-expands-nih-funded-ai-program-into-commercial-alcohol-use-disorder-drug-discovery Tue, 27 Jan 2026 12:10:44 GMT https://www.biospace.com/press-releases/lunai-bioworks-nasdaq-lnai-expands-nih-funded-ai-program-into-commercial-alcohol-use-disorder-drug-discovery https://www.biospace.com/press-releases/demerx-announces-successful-completion-of-multiple-ascending-dose-clinical-trial-of-dmx-1001-for-the-treatment-of-alcohol-use-disorder-aud Tue, 06 Jan 2026 13:45:26 GMT https://www.biospace.com/press-releases/demerx-announces-successful-completion-of-multiple-ascending-dose-clinical-trial-of-dmx-1001-for-the-treatment-of-alcohol-use-disorder-aud https://www.biospace.com/press-releases/clearmind-medicine-announces-positive-top-line-results-from-first-cohort-of-its-fda-approved-phase-i-iia-clinical-trial-for-alcohol-use-disorder Wed, 19 Nov 2025 06:35:00 GMT https://www.biospace.com/press-releases/clearmind-medicine-announces-positive-top-line-results-from-first-cohort-of-its-fda-approved-phase-i-iia-clinical-trial-for-alcohol-use-disorder https://www.biospace.com/press-releases/clearmind-medicine-receives-final-approval-to-expand-its-fda-regulated-phase-1-2a-clinical-trial-for-alcohol-use-disorder-at-hadassah-medical-center Fri, 14 Nov 2025 11:54:39 GMT https://www.biospace.com/press-releases/clearmind-medicine-receives-final-approval-to-expand-its-fda-regulated-phase-1-2a-clinical-trial-for-alcohol-use-disorder-at-hadassah-medical-center https://www.biospace.com/press-releases/brainsway-reports-national-institutes-of-health-grant-to-leading-u-s-research-team-investigating-accelerated-deep-tms-for-treatment-of-alcohol-use-disorder Wed, 05 Nov 2025 10:50:32 GMT https://www.biospace.com/press-releases/brainsway-reports-national-institutes-of-health-grant-to-leading-u-s-research-team-investigating-accelerated-deep-tms-for-treatment-of-alcohol-use-disorder https://www.biospace.com/press-releases/altimmune-announces-early-completion-of-enrollment-in-reclaim-phase-2-trial-evaluating-pemvidutide-in-alcohol-use-disorder Tue, 04 Nov 2025 08:44:07 GMT https://www.biospace.com/press-releases/altimmune-announces-early-completion-of-enrollment-in-reclaim-phase-2-trial-evaluating-pemvidutide-in-alcohol-use-disorder https://www.biospace.com/press-releases/clearmind-medicine-announces-publication-of-u-s-patent-application-targeting-binge-behavior-disorders Tue, 21 Oct 2025 07:42:22 GMT https://www.biospace.com/press-releases/clearmind-medicine-announces-publication-of-u-s-patent-application-targeting-binge-behavior-disorders https://www.biospace.com/press-releases/demerx-awarded-1-7-million-national-institutes-of-health-grant-to-advance-potential-first-in-class-neuroplastogen-drug-candidate-dmx-1001-for-alcohol-use-disorder-aud Wed, 08 Oct 2025 07:05:05 GMT https://www.biospace.com/press-releases/demerx-awarded-1-7-million-national-institutes-of-health-grant-to-advance-potential-first-in-class-neuroplastogen-drug-candidate-dmx-1001-for-alcohol-use-disorder-aud